Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.8286 $TBUFF
Tribute Pharmaceuticals Canada's (TBUFF) CEO Robert Harris on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 11:54AM CDT
Tribute Pharmaceuticals Announces First Quarter 2015 Results
Marketwired - Tue May 12, 6:30AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the first quarter ended March 31, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
Marketwired - Fri May 08, 6:28AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Tuesday, May 12, 2015 at 9:00 AM EDT to review and discuss the Company's results for its first quarter ending March 31, 2015.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
Marketwired - Mon Apr 27, 7:54AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Rob Harris, Chief Executive Officer, will present at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday, May 4, 2015, at 2:00 p.m. ET.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index
Marketwired - Wed Apr 15, 8:53AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced, effective April 20, 2015, the Company will be added to the S&P/TSX Venture Select Index.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference
Marketwired - Thu Apr 02, 8:16AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company" (TSX VENTURE: TRX) (OTCQX: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Mr. Rob Harris, its President and Chief Executive Officer will participate in a Specialty Pharmaceutical Healthcare Panel Discussion to be held on Thursday, April 9, 2015 at 1:35 PM ET at the Laurentian Bank Securities 2nd Annual Investor Conference in Montreal. Mr. Scott Langille, Tribute's Chief Financial Officer will also attend the conference.
TRX.VN: 1.010 (+0.060)
Tribute Raises US$2.7 Million Through the Exercise of Warrants
Marketwired - Thu Mar 19, 5:48PM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that holders of 5,431,250 or 90.1% of the Series A Warrants issued in connection with the Company's 2013 unit financing were exercised prior to their expiry resulting in proceeds to the Company of US$2,715,625.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 2:00PM CST
Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results
Marketwired - Tue Mar 03, 6:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the fourth quarter and year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, March 3, 2015
ACCESSWIRE - Mon Mar 02, 3:07PM CST
MILTON, ON / ACCESSWIRE / March 2, 2015 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2014, to be held Tuesday, March 3, 2015 at 9:00 AM Eastern Time.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants
Marketwired - Mon Mar 02, 8:54AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company", a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that 100% of the participants in Tranche I of the Company's February/March 2013 private placement of units, which included a majority of the Company's officers and directors, have exercised the Series A Warrants (as defined below) acquired by them in such financing prior to their expiration. A total of 4,218,750 Series A Warrants were exercised and an equal amount of common shares of the Company were issued, for an aggregate of US$2,109,375 in proceeds.
TRX.VN: 1.010 (+0.060)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.89 (-0.11), TRIL: 20.35 (+1.78)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Robert Harris on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue May 12, 11:54AM CDT
Tribute Pharmaceuticals Announces First Quarter 2015 Results
Marketwired - Tue May 12, 6:30AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the first quarter ended March 31, 2015. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Schedules First Quarter 2015 Financial Results Conference Call
Marketwired - Fri May 08, 6:28AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Tuesday, May 12, 2015 at 9:00 AM EDT to review and discuss the Company's results for its first quarter ending March 31, 2015. TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Investor Conference
Marketwired - Mon Apr 27, 7:54AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Rob Harris, Chief Executive Officer, will present at the 2015 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Monday, May 4, 2015, at 2:00 p.m. ET. TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index
Marketwired - Wed Apr 15, 8:53AM CDT
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced, effective April 20, 2015, the Company will be added to the S&P/TSX Venture Select Index. TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals to Participate at Laurentian Bank Securities Annual Investor Conference
Marketwired - Thu Apr 02, 8:16AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or the "Company"
(TSX VENTURE: TRX) (OTCQX: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that Mr. Rob Harris, its President and Chief Executive Officer will participate in a Specialty Pharmaceutical Healthcare Panel Discussion to be held on Thursday, April 9, 2015 at 1:35 PM ET at the Laurentian Bank Securities 2nd Annual Investor Conference in Montreal. Mr. Scott Langille, Tribute's Chief Financial Officer will also attend the conference. TRX.VN: 1.010 (+0.060)
Tribute Raises US$2.7 Million Through the Exercise of Warrants
Marketwired - Thu Mar 19, 5:48PM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that holders of 5,431,250 or 90.1% of the Series A Warrants issued in connection with the Company's 2013 unit financing were exercised prior to their expiry resulting in proceeds to the Company of US$2,715,625. TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Canada's (TBUFF) CEO Rob Harris on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Mar 03, 2:00PM CST
Tribute Pharmaceuticals Announces Strong 2014 Fourth Quarter and Year End Results
Marketwired - Tue Mar 03, 6:01AM CST
Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX)(OTCQX: TBUFF) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced its operational and financial results for the fourth quarter and year ended December 31, 2014. Unless otherwise indicated, all dollar amounts included herein are stated in Canadian dollars. TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals to Host Fourth Quarter and Fiscal Year 2014 Earnings Conference Call and Webcast Live on Tuesday, March 3, 2015
ACCESSWIRE - Mon Mar 02, 3:07PM CST
MILTON, ON / ACCESSWIRE / March 2, 2015 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX Venture: TRX) will host a conference call and live webcast to discuss the results of the fourth quarter and fiscal year 2014, to be held Tuesday, March 3, 2015 at 9:00 AM Eastern Time.
TRX.VN: 1.010 (+0.060)
Tribute Pharmaceuticals Board Members and Management Exercise Series A Warrants
Marketwired - Mon Mar 02, 8:54AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced that 100% of the participants in Tranche I of the Company's February/March 2013 private placement of units, which included a majority of the Company's officers and directors, have exercised the Series A Warrants (as defined below) acquired by them in such financing prior to their expiration. A total of 4,218,750 Series A Warrants were exercised and an equal amount of common shares of the Company were issued, for an aggregate of US$2,109,375 in proceeds. TRX.VN: 1.010 (+0.060)
Bloom Burton's David Martin Zeroes In On Under-The-Radar Biotech
Life Sciences Report - Seeking Alpha - Fri Feb 13, 9:24AM CST
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based...
AUPH: 3.89 (-0.11), TRIL: 20.35 (+1.78)
